Multicenter clinical experience of real life Dalbavancin use in gram-positive infections
Dalbavancin, a lipoglycopeptide with prolonged half-life approved for the treatment of acute bacterial skin and soft tissue infections, can be used for the treatment of infections caused by gram-positive bacteria requiring long term treatment such as endocarditis, prosthetic joint infections (PJI) o...
Main Authors: | S. Wunsch, R. Krause, T. Valentin, J. Prattes, O. Janata, A. Lenger, R. Bellmann-Weiler, G. Weiss, I. Zollner-Schwetz |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-04-01
|
Series: | International Journal of Infectious Diseases |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971219300773 |
Similar Items
-
Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections
by: Yuhang Wang, et al.
Published: (2021-03-01) -
Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
by: Luis Buzón-Martín, et al.
Published: (2021-05-01) -
Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series
by: Evins, C., et al.
Published: (2022) -
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
by: Carmen Hidalgo-Tenorio, et al.
Published: (2019-10-01) -
Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections
by: Jacqueline T. Bork, et al.
Published: (2019-05-01)